Italian IRCCS research hospital contributing clinical expertise in cardiovascular disease, cancer immunotherapy, and personalized prevention to European consortia.
IRCCS Ospedale Policlinico San Martino is a major Italian clinical research hospital in Genova that combines patient care with translational biomedical research. Their H2020 work spans cardiovascular disease stratification, cancer immunotherapy (particularly NK cell manufacturing), tissue engineering for bone and cartilage repair, and rapid molecular diagnostics. They contribute clinical expertise and patient cohorts to large European consortia, bridging the gap between laboratory science and bedside application across multiple therapeutic areas.
TAXINOMISIS focused on carotid artery disease stratification using omics and computational modeling, while CoroPrevention targets personalized coronary heart disease prevention through biomarkers and lifestyle interventions.
MATURE-NK addressed manufacturing of tumour-reactive NK cells, including CAR technology and GMP-compliant therapeutic cell production for leukemia and cancer treatment.
CarBon investigated cartilage-to-bone transitions using biomaterials and in silico modeling for treating bone defects and osteoarthritis.
HG nCoV19 test developed LAMP-based rapid diagnostic testing for coronavirus, demonstrating capacity to respond quickly to emerging infectious diseases.
EOSC-Life and IS_MIRRI21 show growing involvement in European open science cloud infrastructure and microbial resource management for biological research.
In their earlier H2020 projects (2017–2018), the hospital focused on bench-to-bedside translational research: tissue engineering for bone and cartilage repair, pharmacogenomics for stroke patients, and NK cell immunotherapy manufacturing. From 2019 onward, their focus shifted toward personalized prevention (coronary heart disease biomarkers, lifestyle interventions), European research data infrastructure (EOSC-Life), and rapid diagnostics in response to the COVID-19 pandemic. This evolution signals a move from laboratory-intensive therapeutic development toward data-driven clinical prevention and digital research infrastructure.
San Martino is moving toward data-driven personalized medicine and digital research infrastructure, making them a strong partner for projects combining clinical cohorts with computational approaches.
San Martino operates exclusively as a consortium partner or third party — they have not coordinated any H2020 projects. They consistently join large consortia (144 unique partners across 22 countries), contributing clinical expertise, patient data, and hospital infrastructure rather than leading project management. This makes them a reliable specialist contributor who brings real-world clinical validation to research consortia without competing for the coordination role.
With 144 unique consortium partners across 22 countries from just 7 projects, San Martino is embedded in large pan-European clinical research networks. Their reach is broad and European-wide, reflecting involvement in major multi-site clinical and infrastructure projects.
As an IRCCS (Istituto di Ricovero e Cura a Carattere Scientifico), San Martino holds a special Italian government designation for hospitals that combine clinical care with scientific research — a status that guarantees access to patient cohorts and clinical validation pathways. Their unusual breadth across cardiovascular, oncology, musculoskeletal, and infectious disease research makes them versatile clinical partners. For consortium builders, they offer something hard to find elsewhere: a single hospital partner that can contribute across multiple disease areas with both laboratory and clinical trial capacity.
